Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Beate Timmermann, Catharina Dhooge et al.|European Journal of Cancer|2019Cited by 724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa Marina, Lisa A. Teot, Sigbjørn Smeland et al.|The Lancet Oncology|2016Cited by 537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Sigbjørn Smeland et al.|Journal of Clinical Oncology|2015Cited by 419
SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized diseaseGabriele Calaminus, Didier Frappaz, Rolf‐Dieter Kortmann et al.|Neuro-Oncology|2013Cited by 371
Long term survivors of childhood cancer: Cure and careRiccardo Haupt, Momcilo Jankovic, John J. Spinetta et al.|European Journal of Cancer|2007Cited by 88